Clinical Trials

A key focus of Andrew McLachlan’s career is understanding the impact of aging on drug disposition and response to medicines.

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

What does the controversial genome editing work of Jiankui He mean for biomedical research?

Only 50 percent of clinical trial results in Europe are reported, but big pharma shares far less than half the blame.

The PRGLAC Task Force hopes to change the landscape for research on pregnant and lactating women.

Including pregnant women in research isn’t as difficult as some might think…

One pharma company is working to pioneer safer drugs for use during pregnancy…

The lack of evidence available from pharma companies to guide care of pregnant women is ethically unacceptable.

Is pharma putting women and children last?

It’s time for maternal health to move on from the dark ages, and pharma has a duty to help.